Ganna Usenko

589 total citations
14 papers, 84 citations indexed

About

Ganna Usenko is a scholar working on Genetics, Hematology and Oncology. According to data from OpenAlex, Ganna Usenko has authored 14 papers receiving a total of 84 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 8 papers in Hematology and 6 papers in Oncology. Recurrent topics in Ganna Usenko's work include Chronic Lymphocytic Leukemia Research (8 papers), Multiple Myeloma Research and Treatments (5 papers) and Advanced Breast Cancer Therapies (3 papers). Ganna Usenko is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Multiple Myeloma Research and Treatments (5 papers) and Advanced Breast Cancer Therapies (3 papers). Ganna Usenko collaborates with scholars based in Ukraine, Czechia and Poland. Ganna Usenko's co-authors include Iryna Kriachok, Ting Yu, Árpád Illés, Martin Šimkovič, Paolo Ghia, Philip Campbell, Małgorzata Wach, Daniel Lysák, Sean Dolan and Abraham Jacob and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ganna Usenko

11 papers receiving 84 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ganna Usenko Ukraine 3 71 61 30 22 18 14 84
Iryna Kriachok Ukraine 4 86 1.2× 70 1.1× 31 1.0× 31 1.4× 17 0.9× 10 93
Yufu Lin China 3 50 0.7× 35 0.6× 18 0.6× 28 1.3× 22 1.2× 10 81
Tommi Salmi United States 5 86 1.2× 75 1.2× 24 0.8× 23 1.0× 17 0.9× 11 96
Marina Deodato Italy 6 75 1.1× 53 0.9× 18 0.6× 22 1.0× 15 0.8× 13 99
S. Stilgenbauer Germany 5 56 0.8× 50 0.8× 10 0.3× 27 1.2× 18 1.0× 19 71
Mariya Salman United Kingdom 5 87 1.2× 83 1.4× 36 1.2× 14 0.6× 9 0.5× 12 91
Éric Durot France 6 65 0.9× 74 1.2× 16 0.5× 22 1.0× 21 1.2× 26 92
Mona Stefanos United States 4 59 0.8× 50 0.8× 39 1.3× 21 1.0× 8 0.4× 4 73
Zachary A. Hing United States 3 62 0.9× 50 0.8× 33 1.1× 30 1.4× 18 1.0× 5 103
M Asuncion Echeveste Spain 3 61 0.9× 46 0.8× 29 1.0× 16 0.7× 8 0.4× 4 75

Countries citing papers authored by Ganna Usenko

Since Specialization
Citations

This map shows the geographic impact of Ganna Usenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ganna Usenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ganna Usenko more than expected).

Fields of papers citing papers by Ganna Usenko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ganna Usenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ganna Usenko. The network helps show where Ganna Usenko may publish in the future.

Co-authorship network of co-authors of Ganna Usenko

This figure shows the co-authorship network connecting the top 25 collaborators of Ganna Usenko. A scholar is included among the top collaborators of Ganna Usenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ganna Usenko. Ganna Usenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Pour, Luděk, Ganna Usenko, Gábor Mikala, et al.. (2024). PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24(6). e267–e275.e2. 1 indexed citations
2.
3.
Pour, Luděk, Jelena Bila, Fredrik Schjesvold, et al.. (2023). Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study. Haematologica. 109(3). 895–905. 6 indexed citations
4.
5.
6.
7.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2022). Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. HemaSphere. 6(12). e801–e801. 65 indexed citations
8.
Ghia, Paolo, Małgorzata Wach, Daniel Lysák, et al.. (2022). P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP. HemaSphere. 6. 566–567. 1 indexed citations
9.
Jurczak, Wojciech, Andrzej Pluta, Małgorzata Wach, et al.. (2022). Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.. Journal of Clinical Oncology. 40(16_suppl). 7538–7538. 3 indexed citations
10.
11.
Minařík, Jiří, Ganna Usenko, Gábor Mikala, et al.. (2021). P-205: PORT (OP-109): Phase 2, randomised, Pharmacokinetic (PK), cross-over study of peripheral vs central intravenous administration of Melflufen in patients with Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 21. S151–S152. 1 indexed citations
12.
Usenko, Ganna, et al.. (2021). Pulmonary comorbidity in chronic lymphoproliferative diseases: realities of the problem in the Dnipro region. SHILAP Revista de lepidopterología. 26(4). 62–67.
13.
Usenko, Ganna, et al.. (2020). Rate of respiratory symptoms in naïve patients with Chronic lymphocytic leukemia. 1913–1913. 2 indexed citations
14.
Kaplan, P. Özge, et al.. (2019). THE INCIDENCE OF MULTIPLE MYELOMA IN THE DNIPROPETROVSK REGION. Проблеми радіаційної медицини та радіобіології = Problems of Radiation Medicine and Radiobiology. 24. 169–179.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Iryna Kriachok Breakdown of academic impact, for papers by Yufu Lin Breakdown of academic impact, for papers by Tommi Salmi Breakdown of academic impact, for papers by Marina Deodato Breakdown of academic impact, for papers by S. Stilgenbauer Breakdown of academic impact, for papers by Mariya Salman Breakdown of academic impact, for papers by Éric Durot Breakdown of academic impact, for papers by Mona Stefanos Breakdown of academic impact, for papers by Zachary A. Hing Breakdown of academic impact, for papers by M Asuncion Echeveste
Rankless by CCL
2026